An estimated 100 million people in the United States live with metabolic dysfunction-associated steatotic liver disease, a chronic condition formerly known as nonalcoholic fatty liver disease, according to the American Liver Foundation. Researchers co-led by Cedars-Sinai Health Sciences University have identified a cellular enzyme that protects the liver from severe damage as this condition progresses, sciencedaily.com reported. The preclinical study, published in Nature Metabolism, pinpoints the UBE2N enzyme as a critical regulator in preventing the shift from simple fat accumulation to advanced liver inflammation and failure.
The Decline of Protective Enzyme Levels in Liver Disease
While roughly 20% to 25% of individuals with steatotic liver disease eventually develop metabolic dysfunction-associated steatohepatitis—a serious condition characterized by excess fat, inflammation, cell injury, and scarring—current treatment options remain limited primarily to lifestyle modifications. Researchers discovered that levels of the UBE2N enzyme drop steadily in liver cells as the disease advances.
When enzyme concentrations fell during laboratory observation, investigators noted a direct increase in cellular damage and tissue injury.
Restoring UBE2N to Reverse Liver Fat and Scarring
To test the therapeutic potential of the enzyme, researchers restored UBE2N to normal levels in the livers of laboratory mice. Following the restoration, the research team observed measurable reductions in hepatic fat accumulation, tissue inflammation, and fibrosis. These outcomes highlight UBE2N as a viable target for future drug development aimed at stopping the progression of early-stage liver disease.
Future clinical trials must determine whether enhancing this pathway can successfully complement existing therapies and identify specific patient populations most likely to benefit.
Funding and Collaborative Research Contributions
The multicenter study involved a broad team of investigators across multiple institutions alongside the Cedars-Sinai research group, which included Michitaka Matsuda, So Yeon Kim, Takashi Tsuchiya, and Yoon Seok Roh.
Financial support for the research came from the National Research Foundation of Korea under grant numbers RS-2025-02273102 and RS-2025-02603096, and the Regional Innovation System and Education programme of Chungbuk under grant number 2025-RISE-11-014-03. Additional backing was provided by the Pinnacle Research Award of the American Association for the Study of Liver Diseases awarded to J.L., a San Diego Digestive Diseases Research Center Pilot and Feasibility Grant under National Institutes of Health grant NIDDK P30 DK120515, National Institutes of Health grants R01DK085252, R01DK138591, and R01CA301632, and the National Natural Science Foundation of China under grant number 82404726.
Worth a look